bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S6 from Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy
Authors: Tsuji Takemasa , Yoneda Akira , Matsuzaki Junko , Miliotto Anthony , Ryan Courtney , Koya Richard C. , Odunsi Kunle
Published: April 2023

Fig. S6 describes tetramer staining of library-derived TCR gene-engineered T cells.
Figure S5 from Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy
Authors: Tsuji Takemasa , Yoneda Akira , Matsuzaki Junko , Miliotto Anthony , Ryan Courtney , Koya Richard C. , Odunsi Kunle
Published: April 2023

Fig. S5 describes characterization of clones in the library by DNA fingerprinting.
Figure S4 from Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy
Authors: Tsuji Takemasa , Yoneda Akira , Matsuzaki Junko , Miliotto Anthony , Ryan Courtney , Koya Richard C. , Odunsi Kunle
Published: April 2023

Fig. S4 describes about the recovery of antigen-specific TCR from plasmid mixtures.
Figure S2 from Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy
Authors: Tsuji Takemasa , Yoneda Akira , Matsuzaki Junko , Miliotto Anthony , Ryan Courtney , Koya Richard C. , Odunsi Kunle
Published: April 2023

Fig. S2 shows the tetramer-staining of MHC class I-restricted TCR gene-engineered T cells.
Supplementary Data from Mapping the MHC Class I–Spliced Immunopeptidome of Cancer Cells
Authors: Liepe Juliane , Sidney John , Lorenz Felix K.M. , Sette Alessandro , Mishto Michele
Published: April 2023

Supplementary data, supplementary tables 1-4, and all supplementary figures
Table S1 from Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
Authors: Wing Anna , Fajardo Carlos Alberto , Posey Avery D. , Shaw Carolyn , Da Tong , Young Regina M. , Alemany Ramon , June Carl H. , Guedan Sonia
Published: April 2023

The file contains the supplementary table S1
Figure S7 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
Authors: Ding Ling , Chen Xi , Xu Xiaqing , Qian Yuli , Liang Guikai , Yao Fengqi , Yao Zhangting , Wu Honghai , Zhang Jieqiong , He Qiaojun , Yang Bo
Published: April 2023

Cell sorting was used to separate low and high PD-L1 expression cells after PARP1 inhibitor administration; Phosphorylation of GSK3β in ovarian cancer cells was not affected by the PARP inhibitor.
Figure S4 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
Authors: Ding Ling , Chen Xi , Xu Xiaqing , Qian Yuli , Liang Guikai , Yao Fengqi , Yao Zhangting , Wu Honghai , Zhang Jieqiong , He Qiaojun , Yang Bo
Published: April 2023

STAT3 is required for Olaparib-induced PD-L1 expression.
Supplementary Figure 3 from Apoptosis-Regulated Low-Avidity Cancer-Specific CD8+ T Cells Can Be Rescued to Eliminate HER2/neu–Expressing Tumors by Costimulatory Agonists in Tolerized Mice
Authors: Black Chelsea M. , Armstrong Todd D. , Jaffee Elizabeth M.
Published: April 2023

PDF file - 134K, Demonstration of the ability of alphaOX40 and alpha41BB agonists to temporarily eliminate established tumors.
Supplementary Figure 2 from Apoptosis-Regulated Low-Avidity Cancer-Specific CD8+ T Cells Can Be Rescued to Eliminate HER2/neu–Expressing Tumors by Costimulatory Agonists in Tolerized Mice
Authors: Black Chelsea M. , Armstrong Todd D. , Jaffee Elizabeth M.
Published: April 2023

PDF file - 99K, Protein expression of DR5, FasL, and CD24 compared between naive low avidity T cells, low avidity T cell activated in vivo, and low avidity T cells activated in vitro.
Supplementary Figure 4 from Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1
Authors: Arnold James N. , Magiera Lukasz , Kraman Matthew , Fearon Douglas T.
Published: April 2023

PDF file - 64K, Assessment of HO-1 expression in FAP+ macrophages in LL2/OVA tumors grown in bone marrow chimeric mice.
Supplementary Figures 1 - 9 from Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Authors: Wang Liang-Chuan S. , Lo Albert , Scholler John , Sun Jing , Majumdar Rajrupa S. , Kapoor Veena , Antzis Michael , Cotner Cody E. , Johnson Laura A. , Durham Amy C. , Solomides Charalambos C. , June Carl H. , Puré Ellen , Albelda Steven M.
Published: April 2023

PDF file - 1196K, Supplementary Figure 1. Phenotypic analysis of FAP+ stromal cells in untreated TC1 flank tumors in C57BL/6 mice. Supplementary Figure 2. Depletion of FAP+ cells. Supplementary Figure 3. Persistence and antitumor activities of FAP-CAR T cells employing either human 4-1BB (73.3-hBBz) or mouse CD28 (73.3-m28z) co-stimulatory domain in mice and their in vitro activity. Supplementary Figure 4. Deletion of DGKzeta enhanced effector functions and in vivo persistence of FAP-CAR T cells. Supplementary Figure 5. Body weight of FAP-CAR T cells-treated mice remained constant or increased. Supplementary Figure 6. Histology of bone marrows and pancreas following treatment with FAP-CAR T cells. Supplementary Figure 7. Activation-induced cell death of FAP-CAR T cells. Supplementary Figure 8. Differential FAP expression on tumor and pancreatic FAP+ stromal cells. Supplementary Figure 9. mAb 73.3 and mAb FAP5 are specific for distinct epitopes of murine FAP expressed by fibroblasts.
Supplementary Figure 1 from Influenza Virus Infection Elicits Protective Antibodies and T Cells Specific for Host Cell Antigens Also Expressed as Tumor-Associated Antigens: A New View of Cancer Immunosurveillance
Authors: Iheagwara Uzoma K. , Beatty Pamela L. , Van Phu T. , Ross Ted M. , Minden Jonathan S. , Finn Olivera J.
Published: April 2023

PDF file - 2331K, Supplementary Figure S1: TAA peptides bind to MHC-I.
Supplementary Figure Legend from Myeloid-Derived Suppressor Cells Attenuate TH1 Development through IL-6 Production to Promote Tumor Progression
Authors: Tsukamoto Hirotake , Nishikata Ryutaro , Senju Satoru , Nishimura Yasuharu
Published: April 2023

PDF file - 86K
Supplementary Figure Legends from GITR Agonism Enhances Cellular Metabolism to Support CD8+ T-cell Proliferation and Effector Cytokine Production in a Mouse Tumor Model
Authors: Sabharwal Simran S. , Rosen David B. , Grein Jeff , Tedesco Dana , Joyce-Shaikh Barbara , Ueda Roanna , Semana Marie , Bauer Michele , Bang Kathy , Stevenson Christopher , Cua Daniel J. , Zúñiga Luis A.
Published: April 2023

Legends for the 3 Supplementary Figure Legends
Supplementary Figure 5 from Myeloid-Derived Suppressor Cells Attenuate TH1 Development through IL-6 Production to Promote Tumor Progression
Authors: Tsukamoto Hirotake , Nishikata Ryutaro , Senju Satoru , Nishimura Yasuharu
Published: April 2023

PDF file - 1482K, Proposed model for MDSC-mediated inhibition of anti-tumor CD4+ T cell response.
Supplementary Figure 4 from Myeloid-Derived Suppressor Cells Attenuate TH1 Development through IL-6 Production to Promote Tumor Progression
Authors: Tsukamoto Hirotake , Nishikata Ryutaro , Senju Satoru , Nishimura Yasuharu
Published: April 2023

PDF file - 1746K, The effect of MDSC-derived IL-6 and sIL-6R on tumor-specific CD4+ T cells.
Figure S2 from GITR Agonism Enhances Cellular Metabolism to Support CD8+ T-cell Proliferation and Effector Cytokine Production in a Mouse Tumor Model
Authors: Sabharwal Simran S. , Rosen David B. , Grein Jeff , Tedesco Dana , Joyce-Shaikh Barbara , Ueda Roanna , Semana Marie , Bauer Michele , Bang Kathy , Stevenson Christopher , Cua Daniel J. , Zúñiga Luis A.
Published: April 2023

MEK/PI3K Data
Supplementary Figures 1 - 5, Tables 1 - 2 from Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th2 and Regulatory Immunity through OX40L and ICOSL
Authors: Aspord Caroline , Leccia Marie-Therese , Charles Julie , Plumas Joel
Published: April 2023

PDF file - 155K, Supplementary Fig. S1: Tumors highly infiltrated by pDCs showed higher breslow. Supplementary Fig. S2: Humanized mouse model. Supplementary Fig. S3: pDCs are more frequent than mDCs in melanoma tumor and DLN Supplementary Fig. S4: Patients with advanced melanoma showed higher levels of OX40L+ pDCs and Th2-skewed T cells in circulation compared to early stages. Supplementary Fig. S5: MDC/CCL22 and MMP2 triggered OX40L and TARC/CCL17 promoted ICOSL on pDCs. Supplementary Table S1 Clinical features of patients from whom tumor samples were used. Supplementary Table S2 Clinical features of patients from who blood samples were used.
Supplementary Figure 1 from Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
Authors: Kitano Shigehisa , Tsuji Takemasa , Liu Caillian , Hirschhorn-Cymerman Daniel , Kyi Chrisann , Mu Zhenyu , Allison James P. , Gnjatic Sacha , Yuan Jianda D. , Wolchok Jedd D.
Published: April 2023

PDF file - 144K, Supplemental Figure 1 NY-ESO-1 antigen-specific CD4+ T cell lines were CD8 negative.
Supplementary Figure 2 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Authors: Gulley James L. , Madan Ravi A. , Tsang Kwong Y. , Jochems Caroline , Marté Jennifer L. , Farsaci Benedetto , Tucker Jo A. , Hodge James W. , Liewehr David J. , Steinberg Seth M. , Heery Christopher R. , Schlom Jeffrey
Published: April 2023

PDF file - 62K, IL-5 following vaccine.
Supplementary Figure 1 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Authors: Gulley James L. , Madan Ravi A. , Tsang Kwong Y. , Jochems Caroline , Marté Jennifer L. , Farsaci Benedetto , Tucker Jo A. , Hodge James W. , Liewehr David J. , Steinberg Seth M. , Heery Christopher R. , Schlom Jeffrey
Published: April 2023

PDF file - 90K, Consort diagram.
Supplementary Table 1 and Supplementary Figures 1 through 7 from Differentiated State of Initiating Tumor Cells Is Key to Distinctive Immune Responses Seen in H-RasG12V–Induced Squamous Tumors
Authors: Podolsky Michael A. , Bailey Jacob T. , Gunderson Andrew J. , Oakes Carrie J. , Breech Kyle , Glick Adam B.
Published: April 2023

Supplementary Table 1: Primers used for genotyping and qRT-PCR. Supplementary Figure 1: Establishment of murine models of targeted H-RasV12G to basal and suprabasal layers of the epidermis. Supplementary Figure 2: Leukocyte infiltration into K14Ras and InvRas tumors correlates with tumor number and basal cell proliferation. Supplementary Figure 3: Cytokine expression and MDSC suppression assays display distinct immunosuppressive phenotypes in K14Ras mice. Supplementary Figure 4: CD8 or CD8 + B Cell transfers do not restore Rag1+/+ tumor counts or B cell phenotypes. Supplementary Figure 5: Adoptive co-transfer of CD4 T Cells and B cells selectively restores Rag1+/+ cytokine expression. Supplementary Figure 6: Dendritic Cell activity in hyperplastic skin or SDLNs does not significantly contribute to the overall Ras-induced immune response. Supplementary Figure 7: Adoptively transferred B cells migrate directly to the tumor microenvironment following Ras activation.
Supplementary Figure 3 from CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains
Authors: Shiina Satoshi , Ohno Masasuke , Ohka Fumiharu , Kuramitsu Shunichiro , Yamamichi Akane , Kato Akira , Motomura Kazuya , Tanahashi Kuniaki , Yamamoto Takashi , Watanabe Reiko , Ito Ichiro , Senga Takeshi , Hamaguchi Michinari , Wakabayashi Toshihiko , Kaneko Mika K. , Kato Yukinari , Chandramohan Vidyalakshmi , Bigner Darell D. , Natsume Atsushi
Published: April 2023

Intracellular cytokine staining. Effector cells (2 Ã— 105 cells of mock-transduced PBMCs) were incubated with 4 Ã— 105 target cells (LN319) in 200 Î¼L RPMI-1640 along with GolgiStop in a round-bottom, 96-well plate. Following a 4 h incubation at 37{degree sign}C, the cells were incubated with biotin-SP-AffiniPure F(ab')2 fragment-specific goat anti-mouse IgG at 4{degree sign}C for 30 min. The mock-CAR CD8-T and CD4-T cells did not produce IFN-Î³, TNF-Î±, IL-2, and CD107a.
Supplementary Figure S1 from Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer
Authors: Scheid Elizabeth , Major Pierre , Bergeron Alain , Finn Olivera J. , Salter Russell D. , Eady Robin , Yassine-Diab Bader , Favre David , Peretz Yoav , Landry Claire , Hotte Sebastien , Mukherjee Som D. , Dekaban Gregory A. , Fink Corby , Foster Paula J. , Gaudet Jeffery , Gariepy Jean , Sekaly Rafick-Pierre , Lacombe Louis , Fradet Yves , Foley Ronan
Published: April 2023

Quality control of DC vaccine preparations.
Supplementary Figure Legends from Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer
Authors: Scheid Elizabeth , Major Pierre , Bergeron Alain , Finn Olivera J. , Salter Russell D. , Eady Robin , Yassine-Diab Bader , Favre David , Peretz Yoav , Landry Claire , Hotte Sebastien , Mukherjee Som D. , Dekaban Gregory A. , Fink Corby , Foster Paula J. , Gaudet Jeffery , Gariepy Jean , Sekaly Rafick-Pierre , Lacombe Louis , Fradet Yves , Foley Ronan
Published: April 2023

Legends of Supplementary Figures S1 to S6
Supplementary Figure S5 from IFNγ Induces DNA Methylation–Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
Authors: Bardhan Kankana , Paschall Amy V. , Yang Dafeng , Chen May R. , Simon Priscilla S. , Bhutia Yangzom D. , Martin Pamela M. , Thangaraju Muthusamy , Browning Darren D. , Ganapathy Vadivel , Heaton Christopher M. , Gu Keni , Lee Jeffrey R. , Liu Kebin
Published: April 2023

Figure S5: Immunohistochemical staining of CD8+ T cell infiltration level in colon carcinoma tissues from 10 patients. The brown color indicates specific CD8+ T cells.
Supplemental Figure Legend from IFNγ Induces DNA Methylation–Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
Authors: Bardhan Kankana , Paschall Amy V. , Yang Dafeng , Chen May R. , Simon Priscilla S. , Bhutia Yangzom D. , Martin Pamela M. , Thangaraju Muthusamy , Browning Darren D. , Ganapathy Vadivel , Heaton Christopher M. , Gu Keni , Lee Jeffrey R. , Liu Kebin
Published: April 2023

Supplemental Data
Supplemental Figure S2 from Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
Authors: Berrien-Elliott Melissa M. , Yuan Jinyun , Swier Lauryn E. , Jackson Stephanie R. , Chen Collin L. , Donlin Maureen J. , Teague Ryan M.
Published: April 2023

CXCR3 is not required for effector function under blockade conditions.
Supplementary Figure 2 from PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
Authors: Severson Jill J. , Serracino Hilary S. , Mateescu Valerica , Raeburn Christopher D. , McIntyre Robert C. , Sams Sharon B. , Haugen Bryan R. , French Jena D.
Published: April 2023

Supplementary Figure 2. PMA/ionomycin and anti-CD3/anti-CD28 induce up-regulation of PD-1 and Tim-3. Non-adherent cells from TILN were left untreated (US) or stimulated with anti-CD3/anti-CD28 or PMA/ionomycin (P/I) for 6 hours to assess cytokine expression. Expression of PD-1 and Tim-3 was analyzed concomitantly by flow cytometry.
Supplementary Figure 5 from Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
Authors: Beavis Paul A. , Milenkovski Nicole , Henderson Melissa A. , John Liza B. , Allard Bertrand , Loi Sherene , Kershaw Michael H. , Stagg John , Darcy Phillip K.
Published: April 2023

This supplementary Figure shows the expression of A2A and IFNy on tumor infiltrating lymphocytes following PD-1 blockade.
Supplementary Figure 3 from Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
Authors: Beavis Paul A. , Milenkovski Nicole , Henderson Melissa A. , John Liza B. , Allard Bertrand , Loi Sherene , Kershaw Michael H. , Stagg John , Darcy Phillip K.
Published: April 2023

This figure shows the proliferation and phneotype of tumor lines in response to NECA.
Supplementary Figures 1-4 with figure legends from Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry
Authors: Woods Amber N. , Wilson Ashley L. , Srivinisan Nithya , Zeng Jianhao , Dutta Arun B. , Peske J. David , Tewalt Eric F. , Gregg Randal K. , Ferguson Andrew R. , Engelhard Victor H.
Published: April 2023

S1: LLC-OVA or MC-38-OVA tumors were harvested on day 14 (SC) or day 11 (IP). LLC-OVA tumors were flash frozen and stained for MadCAM-1 expression. Representative and summary data interrogating 8-10 random fields from single sections of 3 tumors each for the percent of CD31+ pixels that were MadCAM-1+. Percentages were calculated using ImageJ to define CD31+ pixels and quantitating those positive for MadCAM-1. MC-38-OVA tumors were digested and stained for flow cytometry. Summary data (n=2 tumors per group) for the percent of CD31+CD45+ cells that expressed E-Selectin. Statistical analysis performed using unpaired student's T-test. S2: B16-OVA tumors were harvested on day 21 (Lung) or day 13 (Brain) and dissociated and stained for fow cytometric analysis. Representative and summary data for expression of VCAM-1, E-selectin, and MadCAM-1 endothelial cells isolated from lung and brain tumors (n=4). Plots are gated on CD31+CD45- cells. S3: B16-OVA and B16-F1 tumors were harvested on day 14 (SC) or day 11 (IP) and flash frozen for immunofluorescence staining with anti-CD8. Summary data interrogating 5 random 200X fields from single sections of 2 tumors to assess the number of CD8 T-cells. Statistical analysis performed using unpaired student's T-test. 4: CD8 effector T-cells were generated using SIINFEKL pulsed BMDCs administered IV, IP, or SC as described in the legends to Figures 4 and 5. Freshly isolated ex vivo effectors were stained with the indicated antibodies and analyzed by flow cytometry. Plots are gated on CD45+CD8+Thy1.1+ cells.
Supplementary Materials and Methods from Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor
Authors: Tähtinen Siri , Grönberg-Vähä-Koskela Susanna , Lumen Dave , Merisalo-Soikkeli Maiju , Siurala Mikko , Airaksinen Anu J. , Vähä-Koskela Markus , Hemminki Akseli
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure Legends from Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor
Authors: Tähtinen Siri , Grönberg-Vähä-Koskela Susanna , Lumen Dave , Merisalo-Soikkeli Maiju , Siurala Mikko , Airaksinen Anu J. , Vähä-Koskela Markus , Hemminki Akseli
Published: April 2023

Supplementary Figure Legends
supplemental S-2 from The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8+ T-cell Function
Authors: Frey Alan B.
Published: April 2023

Table of TIL ISR from gene array
Supplementary Figure 2 from Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Authors: Sharabi Andrew B. , Nirschl Christopher J. , Kochel Christina M. , Nirschl Thomas R. , Francica Brian J. , Velarde Esteban , Deweese Theodore L. , Drake Charles G.
Published: April 2023

Supp Figure 2. Treg depletion enhances development of endogenous radiation-induced antigen-specific immune reponses in B16-OVA melanoma.
Supplementary Figure Legends from Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
Authors: Cullis Jane , Siolas Despina , Avanzi Antonina , Barui Sugata , Maitra Anirban , Bar-Sagi Dafna
Published: April 2023

Figure legends for supplementary figures 1-3
Supplementary Table 1 from Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach
Authors: Johanns Tanner M. , Ward Jeffrey P. , Miller Christopher A. , Wilson Courtney , Kobayashi Dale K. , Bender Diane , Fu Yujie , Alexandrov Anton , Mardis Elaine R. , Artyomov Maxim N. , Schreiber Robert D. , Dunn Gavin P.
Published: April 2023

GL261 Composite
Supplementary Table 1, Figures 1 - 2 from Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
Authors: Thommen Daniela S. , Schreiner Jens , Müller Philipp , Herzig Petra , Roller Andreas , Belousov Anton , Umana Pablo , Pisa Pavel , Klein Christian , Bacac Marina , Fischer Ozana S. , Moersig Wolfgang , Savic Prince Spasenija , Levitsky Victor , Karanikas Vaios , Lardinois Didier , Zippelius Alfred
Published: April 2023

Supplementary Table 1. Clinical data of NSCLC patients. Supplementary Figure 1. Calculation of the iR score. Supp. Figure 2. Activation of PBMC from healthy donors by polyclonal stimulation.
Supplementary Figure S7 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Authors: Winograd Rafael , Byrne Katelyn T. , Evans Rebecca A. , Odorizzi Pamela M. , Meyer Anders R.L. , Bajor David L. , Clendenin Cynthia , Stanger Ben Z. , Furth Emma E. , Wherry E. John , Vonderheide Robert H.
Published: April 2023

Supplementary Figure S7. Tumor growth curves of individual mice with subcutaneous PDA treated as indicated.
Supplementary Figure S6 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Authors: Winograd Rafael , Byrne Katelyn T. , Evans Rebecca A. , Odorizzi Pamela M. , Meyer Anders R.L. , Bajor David L. , Clendenin Cynthia , Stanger Ben Z. , Furth Emma E. , Wherry E. John , Vonderheide Robert H.
Published: April 2023

Supplementary Figure S6. Antitumor effect of αCD40/chemotherapy is macrophage independent.
Supplementary Table S1 from MicroRNA MIR21 and T Cells in Colorectal Cancer
Authors: Mima Kosuke , Nishihara Reiko , Nowak Jonathan A. , Kim Sun A. , Song Mingyang , Inamura Kentaro , Sukawa Yasutaka , Masuda Atsuhiro , Yang Juhong , Dou Ruoxu , Nosho Katsuhiko , Baba Hideo , Giovannucci Edward L. , Bowden Michaela , Loda Massimo , Giannakis Marios , Bass Adam J. , Dranoff Glenn , Freeman Gordon J. , Chan Andrew T. , Fuchs Charles S. , Qian Zhi Rong , Ogino Shuji
Published: April 2023

Spearman rank-correlation coefficient (r) between the densities of T-cells
Supplementary Figure S3 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Authors: Winograd Rafael , Byrne Katelyn T. , Evans Rebecca A. , Odorizzi Pamela M. , Meyer Anders R.L. , Bajor David L. , Clendenin Cynthia , Stanger Ben Z. , Furth Emma E. , Wherry E. John , Vonderheide Robert H.
Published: April 2023

Supplementary Figure S3. CTLA-4 expression on T cell subsets in mice bearing subcutaneous PDA tumors.
Supplementary Figure S1 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Authors: Winograd Rafael , Byrne Katelyn T. , Evans Rebecca A. , Odorizzi Pamela M. , Meyer Anders R.L. , Bajor David L. , Clendenin Cynthia , Stanger Ben Z. , Furth Emma E. , Wherry E. John , Vonderheide Robert H.
Published: April 2023

Supplementary Figure S1. PD-L1 expression in human PDA.
Supplemental Figure 3 from Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Authors: Tran Linda , Allen Clint T. , Xiao Roy , Moore Ellen , Davis Ruth , Park So-Jin , Spielbauer Katie , Van Waes Carter , Schmitt Nicole C.
Published: April 2023

S3. Cisplatin and anti-PD-L1 blockade induced a slight but short-lived delay of tumor growth in MOC2 tumor-bearing mice that did not improve survival. Mice were injected with 1 x 105 MOC2 tumor cells in the right flank. After 14 days, mice with palpable tumors were randomized and treated concurrently with cisplatin (5 mg/kg/week) and/or anti-PD-L1 antibody (200 mcg twice/week x 3 doses). Black line: control; Blue line: CDDP only; Gray line: anti-PD-L1; Green line: combination. A, Tumor volume over time. Data are mean {plus minus} SEM, n = 8 mice per group. *p<0.05 vs. control by linear regression curve comparison. B, Kaplan-Meier survival plot.
Supplemental Figure Legends from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Authors: Griesinger Andrea M. , Josephson Rebecca J. , Donson Andrew M. , Mulcahy Levy Jean M. , Amani Vladimir , Birks Diane K. , Hoffman Lindsey M. , Furtek Steffanie L. , Reigan Phillip , Handler Michael H. , Vibhakar Rajeev , Foreman Nicholas K.
Published: April 2023

Supplemental Figure Legends
Supplementary Figure S7 from Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Authors: Chu Yaya , Hochberg Jessica , Yahr Ashlin , Ayello Janet , van de Ven Carmella , Barth Matthew , Czuczman Myron , Cairo Mitchell S.
Published: April 2023

Supplementary Fig.S7: Proposed scientific model We propose that the interaction between anti-CD20 CAR on exPBNK and CD20 on the surface of B-L/L transmits activating signal back to exPBNK and significantly stimulates exPBNK degranulation and release of cytokine such as IFN-y to lyse resistant tumor targets.
Supplementary Figure 3 from Restoring Retinoic Acid Attenuates Intestinal Inflammation and Tumorigenesis in APCMin/+ Mice
Authors: Penny Hweixian Leong , Prestwood Tyler R. , Bhattacharya Nupur , Sun Fionna , Kenkel Justin A. , Davidson Matthew G. , Shen Lei , Zuniga Luis A. , Seeley E. Scott , Pai Reetesh , Choi Okmi , Tolentino Lorna , Wang Jinshan , Napoli Joseph L. , Engleman Edgar G.
Published: April 2023

Sorting strategy to obtain DCs and DC subsets from the LP.
Supplementary Figure S1 from Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Authors: Chu Yaya , Hochberg Jessica , Yahr Ashlin , Ayello Janet , van de Ven Carmella , Barth Matthew , Czuczman Myron , Cairo Mitchell S.
Published: April 2023

Supplementary Fig.S1: Anti-CD20 CAR enhances NK92 cells in-vitro cytolytic activity against CD20+ B-NHL cells by retroviral transduction. (A) Schematic representation of the anti-CD20 chimeric receptor in an RD114-pseudotyped retroviral vector. LTR indicates long terminal repeat; AMP, ampicillin resistance. (B)-(C) Expression of anti-CD20 CAR was confirmed in infected Jurkat cells by flow cytometry after staining with a goat anti-mouse (Fab)2 polyclonal antibody conjugated with biotin followed by streptavidin PE (y-axes); expression of GFP is also shown (x-axes) (B) and it was also confirmed in infected PBMC by western blot analysis with an anti-human CD3ï�º antibody (C). (D) NK92 cells expressing anti-CD20 chimeric receptors or expression GFP only were incubated with BATDA labeled targets: CD20+ NK sensitive Ramos, CD20+ NK resistant Daudi and the CD20- pre-B-ALL cell line RS4;11 at the indicated E/ T ratios for 4 hours. Europium release assays were performed according to the manufacturer's instructions. Each data point represents the mean (SEM; n=3). Average values are reported as the mean {plus minus} SEM. p values using unpaired student t test were noted in (D).
Supplementary Figure 5 from Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Authors: Théate Ivan , van Baren Nicolas , Pilotte Luc , Moulin Pierre , Larrieu Pierre , Renauld Jean-Christophe , Hervé Caroline , Gutierrez-Roelens Ilse , Marbaix Etienne , Sempoux Christine , Van den Eynde Benoît J.
Published: April 2023

Kinetics of LPS-induced DC maturation.
Supplemental References from Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Authors: Théate Ivan , van Baren Nicolas , Pilotte Luc , Moulin Pierre , Larrieu Pierre , Renauld Jean-Christophe , Hervé Caroline , Gutierrez-Roelens Ilse , Marbaix Etienne , Sempoux Christine , Van den Eynde Benoît J.
Published: April 2023

Supplemental References
Supplementary Table 2 from Exome Sequencing to Predict Neoantigens in Melanoma
Authors: Pritchard Antonia L. , Burel Julie G. , Neller Michelle A. , Hayward Nicholas K. , Lopez J. Alejandro , Fatho Martina , Lennerz Volker , Wölfel Thomas , Schmidt Christopher W.
Published: April 2023

Total raw dataset of assessment of potential neoepitope sequences through epitope prediction programs for D05, D14, D41, A02 and A06.
Supplementary Figure 2 from Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
Authors: Zippelius Alfred , Schreiner Jens , Herzig Petra , Müller Philipp
Published: April 2023

Supplementary Figure 2. PD-L1 expression, tumor growth and CD8/Treg ratios.
Supplementary Figure 3 from Exome Sequencing to Predict Neoantigens in Melanoma
Authors: Pritchard Antonia L. , Burel Julie G. , Neller Michelle A. , Hayward Nicholas K. , Lopez J. Alejandro , Fatho Martina , Lennerz Volker , Wölfel Thomas , Schmidt Christopher W.
Published: April 2023

Populations of IFNγ high and IFNγ low in response to tumour/peptide stimulation in MLTC at day 34 in patients (A) D05 and (B) D14
Supplementary Figure S3 from Generation of Mouse Pluripotent Stem Cell–Derived Proliferating Myeloid Cells as an Unlimited Source of Functional Antigen-Presenting Cells
Authors: Zhang Rong , Liu Tian-Yi , Senju Satoru , Haruta Miwa , Hirosawa Narumi , Suzuki Motoharu , Tatsumi Minako , Ueda Norihiro , Maki Hiroyuki , Nakatsuka Ryusuke , Matsuoka Yoshikazu , Sasaki Yutaka , Tsuzuki Shinobu , Nakanishi Hayao , Araki Ryoko , Abe Masumi , Akatsuka Yoshiki , Sakamoto Yasushi , Sonoda Yoshiaki , Nishimura Yasuharu , Kuzushima Kiyotaka , Uemura Yasushi
Published: April 2023

Protection against subcutaneously inoculated OVA-expressing melanoma by OVA-peptide loaded iPS-pMC-DCs.
Supplementary Figure 1A from Exome Sequencing to Predict Neoantigens in Melanoma
Authors: Pritchard Antonia L. , Burel Julie G. , Neller Michelle A. , Hayward Nicholas K. , Lopez J. Alejandro , Fatho Martina , Lennerz Volker , Wölfel Thomas , Schmidt Christopher W.
Published: April 2023

For each patient studied, five epitope prediction programs were used to assess potential neoepitopes. The ability of each algorithm to detect neoepitopes per mutation is compared. These graphs show the numbers of mutations for which at least one epitope was predicted compared to those where no prediction was made, for individual patients and overall.
Supplementary Figure 6 from Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Authors: Gabrielson Andrew , Wu Yunan , Wang Hongkun , Jiang Jiji , Kallakury Bhaskar , Gatalica Zoran , Reddy Sandeep , Kleiner David , Fishbein Thomas , Johnson Lynt , Island Eddie , Satoskar Rohit , Banovac Filip , Jha Reena , Kachhela Jaydeep , Feng Perry , Zhang Tiger , Tesfaye Anteneh , Prins Petra , Loffredo Christopher , Marshall John , Weiner Louis , Atkins Michael , He Aiwu Ruth
Published: April 2023

Kaplan-Meier analysis of RFS stratified by pattern of CD3+ and CD8+ T lymphocytes.
Supplementary Figure S1 from Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers
Authors: Noonepalle Satish K. , Gu Franklin , Lee Eun-Joon , Choi Jeong-Hyeon , Han Qimei , Kim Jaejik , Ouzounova Maria , Shull Austin Y. , Pei Lirong , Hsu Pei-Yin , Kolhe Ravindra , Shi Fang , Choi Jiseok , Chiou Katie , Huang Tim H.M. , Korkaya Hasan , Deng Libin , Xin Hong-Bo , Huang Shuang , Thangaraju Muthusamy , Sreekumar Arun , Ambs Stefan , Tang Shou-Ching , Munn David H. , Shi Huidong
Published: April 2023

Cytokine arrays showing cytokine profiles of activated T cells from two healthy donors.
Supplementary Figure 4 from Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Authors: Gabrielson Andrew , Wu Yunan , Wang Hongkun , Jiang Jiji , Kallakury Bhaskar , Gatalica Zoran , Reddy Sandeep , Kleiner David , Fishbein Thomas , Johnson Lynt , Island Eddie , Satoskar Rohit , Banovac Filip , Jha Reena , Kachhela Jaydeep , Feng Perry , Zhang Tiger , Tesfaye Anteneh , Prins Petra , Loffredo Christopher , Marshall John , Weiner Louis , Atkins Michael , He Aiwu Ruth
Published: April 2023

Graphical distributions of CD3+ and CD8+ T lymphocyte densities in the TI and IM.
Fragale et al_Supplementary Fig. S4_CIR from Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells
Authors: Fragale Alessandra , Romagnoli Giulia , Licursi Valerio , Buoncervello Maria , Del Vecchio Giorgia , Giuliani Caterina , Parlato Stefania , Leone Celeste , De Angelis Marta , Canini Irene , Toschi Elena , Belardelli Filippo , Negri Rodolfo , Capone Imerio , Presutti Carlo , Gabriele Lucia
Published: April 2023

Supplementary Figure 4 shows Viability graphs and Sytox staining of IL4-ARI DC and IFN-lambda1, IFNLR1, IFN-betaand IFN-panalpha expression graphs by RT-qPCR in IL4-ARI DC.
Supplementary Figures S1-S13 from Whole Exome and Transcriptome Analyses Integrated with Microenvironmental Immune Signatures of Lung Squamous Cell Carcinoma
Authors: Seo Jeong-Sun , Lee Ji Won , Kim Ahreum , Shin Jong-Yeon , Jung Yoo Jin , Lee Sae Bom , Kim Yoon Ho , Park Samina , Lee Hyun Joo , Park In-Kyu , Kang Chang-Hyun , Yun Ji-Young , Kim Jihye , Kim Young Tae
Published: April 2023

Supplementary Figure S1. Transcriptomic analyses for molecular subtypes Supplementary Figure S2. Identification of the subtypes in LUSC TCGA cohort (n=431) Supplementary Figure S3. The genomic difference across subtypes in LUSC. Supplementary Figure S4. Estimation of Stromal and immune score and distribution of infiltrating immune cells for tumor and noncancer control sample in LUSC Supplementary Figure S5. The immune landscape and micro-environmental signature in LUSC TCGA cohort (n=431) Supplementary Figure S6. The dual roles of stroma are described by distinct gene expression patterns in tumor(subtype A and B) and noncancer control samples. Supplementary Figure S7. Distribution of infiltrating immune cells for tumor and noncancer control sample in LUSC Supplementary Figure S8. Distinct expression pattern of M1 and M2 signature genes in LUSC subtypes Supplementary Figure S9. Comparison of immune contents between subtypes in our LUSC cohort (n=101) and TCGA LUSC cohort (n=431) Supplementary Figure S10. Immune related pathways enriched for genes which have copy number variants. Supplementary Figure S11. Comparison of the LUSC expression subtypes with the previously defined subtypes Supplementary Figure S12. Clinical association analysis across subtypes Supplementary Figure S13. Survival analysis across subtypes
Figure S2 from CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy
Authors: Doorduijn Elien M. , Sluijter Marjolein , Salvatori Daniela C. , Silvestri Serenella , Maas Saskia , Arens Ramon , Ossendorp Ferry , van der Burg Sjoerd H. , van Hall Thorbald
Published: April 2023

Class I and II upregulation, effect type I IFN signalling and late depletions
Supplementary Figure S7. ADU-S100 sequenced with OX40 receptor ligation and PD-L1 blockade significantly delay tumor growth in distal un-injected tumors from neu/N mice. from A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Authors: Foote Jeremy B. , Kok Marleen , Leatherman James M. , Armstrong Todd D. , Marcinkowski Bridget C. , Ojalvo Laureen S. , Kanne David B. , Jaffee Elizabeth M. , Dubensky Thomas W. , Emens Leisha A.
Published: April 2023

Neu/N mice were received 5 x 104 NT2.5 cells in the right cranial mammary fat pad (proximal injected) and left dorsal gluteal subcutaneous tissue (distal un-injected). When tumor sizes reached 62.5-mm3 (5 x 5 mm) neu/N mice were administered IT injections of ADU-S100 or HBSS with or without αOX40 receptor agonistic and αPD-L1 antagonistic antibodies as previously described in the material and methods section. Tumor growth in the injected NT2.5 tumor (proximal injected) and dorsal gluteal (distal un-injected) were evaluated over the course of 50 days. This data is cumulative of two independent experiments of 5 mice/group.
Supplementary Figure S6. Expression of PD-1:PD-L1 pathway is modulated by IT ADU-S100 injections in neu/N mice. from A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Authors: Foote Jeremy B. , Kok Marleen , Leatherman James M. , Armstrong Todd D. , Marcinkowski Bridget C. , Ojalvo Laureen S. , Kanne David B. , Jaffee Elizabeth M. , Dubensky Thomas W. , Emens Leisha A.
Published: April 2023

(A) Expression of immune checkpoint receptors on CD4+ T cells in the TME. (B) Expression of PD-L1 on myeloid and tumor cells in the spleen and TME. (C-D) Increased expression of PD-1 on CD8+ T cells (C) and PD-L1 on myeloid cells (D) was noted 24 hours after IT ADU-S100 injection (gray bar) vs. HBSS (black bar). Statistical significance is determined by student''s t-test. * p < 0.05, ** p<0.01, and *** p<0.001, and **** p<0.0001.
Figure S6 from Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types
Authors: Rhee Je-Keun , Jung Yu Chae , Kim Kyu Ryung , Yoo Jinseon , Kim Jeeyoon , Lee Yong-Jae , Ko Yoon Ho , Lee Han Hong , Cho Byoung Chul , Kim Tae-Min
Published: April 2023

S6. Relative abundance of CM and CMM gene pairs across tumor types.
Supplementary Figure S2. ADU-S100 induces apoptosis and necrosis of established tumors in tumor bearing, non-tolerant FVB/N and tolerant neu/N mice. from A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Authors: Foote Jeremy B. , Kok Marleen , Leatherman James M. , Armstrong Todd D. , Marcinkowski Bridget C. , Ojalvo Laureen S. , Kanne David B. , Jaffee Elizabeth M. , Dubensky Thomas W. , Emens Leisha A.
Published: April 2023

(A-B) Tumor-bearing FVB/N and neu/N mice were treated with 1 dose of ADU-S100, and 24 hours later (A) necrotic tumor cells were evaluated by hematoxylin and eosin staining. (B) The surface area of necrosis in ADU-S100- and HBSS-treated FVB/N and neu/N mice was scored. At 24 hours post IT injection of ADU-S100 or HBSS numbers of activated caspase 3+ cells were evaluated by hematoxylin and eosin in FVB/N and neu/N mice. (C) A representative stain for active caspase 3 is shown for an ADU-S100 tumor from FVB/N mouse. (D) Relative active caspase 3 scored from treated FVB/N and neu/N mice are shown. Data is representative of 3 independent experiments of 5 mice/group. * p < 0.05, ** p<0.01, and *** p<0.001, and **** p<0.0001.
Figure S5 from Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types
Authors: Rhee Je-Keun , Jung Yu Chae , Kim Kyu Ryung , Yoo Jinseon , Kim Jeeyoon , Lee Yong-Jae , Ko Yoon Ho , Lee Han Hong , Cho Byoung Chul , Kim Tae-Min
Published: April 2023

S5. The relationship between survival and CYT expression with purity adjusted.
Supplemental tables and figures from NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors
Authors: DeVette Christa I. , Andreatta Massimo , Bardet Wilfried , Cate Steven J. , Jurtz Vanessa I. , Jackson Kenneth W. , Welm Alana L. , Nielsen Morten , Hildebrand William H.
Published: April 2023

Supplemental Table S1: AUC and PPV for NetH2pan network ensemble Supplemental Table S2: AUC and PPV for prediction of ligands by NetH2pan, trained with or without sequence context of five residues flanking the peptide. Supplemental Table S3. Yield (# of peptides) from soluble MHC transfectants and MMTV-PyMT tumors. Supplemental Table S4. Cancer-associated peptides eluted from MMTV-PyMT tumors. Supplemental Figure S1. MHC Class I peptide tissue extraction approach. Supplemental Figure S2. Peptide overlap with soluble MHC peptide elution and primary tumor cell elution. Supplemental Figure S3. MMTV-PyMT tumors express Class I MHC.
Sup. Table 2 from Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study
Authors: Eshet Yael , Baruch Erez Nissim , Shapira-Frommer Ronnie , Steinberg-Silman Yael , Kuznetsov Teodor , Ben-Betzalel Guy , Daher Sameh , Gluck Iris , Asher Nethanel , Apter Sara , Schachter Jacob , Bar Jair , Boursi Ben , Markel Gal
Published: April 2023

Supplementary table 2 (AEs of PA patients)
Supplementary S5 from Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
Authors: Bartolacci Caterina , Andreani Cristina , Curcio Claudia , Occhipinti Sergio , Massaccesi Luca , Giovarelli Mirella , Galeazzi Roberta , Iezzi Manuela , Tilio Martina , Gambini Valentina , Wang Junbiao , Marchini Cristina , Amici Augusto
Published: April 2023

Anti-tumor effect triggered by phage-based vaccines in Î"16HER2 mice
Suppplementary Information from Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity
Authors: Leshem Yasmin , O'Brien James , Liu Xiufen , Bera Tapan K. , Terabe Masaki , Berzofsky Jay A. , Bossenmaier Birgit , Niederfellner Gerhard , Tai Chin-Hsien , Reiter Yoram , Pastan Ira
Published: April 2023

Fig S1. Description of DNA constructs Fig S2. Distribution of intra-tumoral injected trypan blue Fig S3. Combination of intra-tumoral immunotoxins with anti-CTLA-4 is well tolerated by mice. Fig S4. Anti-tumor effect of anti-CTLA-4 and LMB-100 depends on CD8+ cells. Fig S5. High dose of SS1P is needed for induction of complete remission. Fig S6A & B. Anti-tumor effect of an immunotoxin targeting human CD22 & (B) Combination of SS1P with anti-CTLA-4 lead to tumor regressionof 66C14 tumors not expressing MSLN. Fig S7. Intra-tumors injection of paclitaxel does not improve the anti-tumor activity of anti-CTLA-4. Table S1. Combination of RIT and anti-CTLA-4 induces long-term anti-tumor immunity.
Supplemental Figure 2 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Authors: Santini Fernando C. , Rizvi Hira , Plodkowski Andrew J. , Ni Andy , Lacouture Mario E. , Gambarin-Gelwan Maya , Wilkins Olivia , Panora Elizabeth , Halpenny Darragh F. , Long Niamh M. , Kris Mark G. , Rudin Charles M. , Chaft Jamie E. , Hellmann Matthew D.
Published: April 2023

Overall Survival for Patients in the Retreatment Cohort
Supplementary Table 3 from A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
Authors: Lizotte Patrick H. , Hong Ruey-Long , Luster Troy A. , Cavanaugh Megan E. , Taus Luke J. , Wang Stephen , Dhaneshwar Abha , Mayman Naomi , Yang Aaron , Kulkarni Meghana , Badalucco Lauren , Fitzpatrick Erica , Kao Hsiang-Fong , Kuraguchi Mari , Bittinger Mark , Kirschmeier Paul T. , Gray Nathanael S. , Barbie David A. , Jänne Pasi A.
Published: April 2023

Table 3 SCCHN clinical info
Supplementary Table S3 from CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction
Authors: Siriwon Natnaree , Kim Yu Jeong , Siegler Elizabeth , Chen Xianhui , Rohrs Jennifer A. , Liu Yarong , Wang Pin
Published: April 2023

Statistical analysis of tumor growth curve
Supplementary Fig S1 from CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction
Authors: Siriwon Natnaree , Kim Yu Jeong , Siegler Elizabeth , Chen Xianhui , Rohrs Jennifer A. , Liu Yarong , Wang Pin
Published: April 2023

3D confocal image of CART-cMLV conjugation
Figure S6 from Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
Authors: Ager Casey R. , Reilley Matthew J. , Nicholas Courtney , Bartkowiak Todd , Jaiswal Ashvin R. , Curran Michael A.
Published: April 2023

TIL flow analysis experimental setup and gating strategy
Figure S4 from Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
Authors: Ager Casey R. , Reilley Matthew J. , Nicholas Courtney , Bartkowiak Todd , Jaiswal Ashvin R. , Curran Michael A.
Published: April 2023

Tumor relapse rates
Supplementary information from Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia
Authors: Bernson Elin , Hallner Alexander , Sander Frida E. , Nicklasson Malin , Nilsson Malin S. , Christenson Karin , Aydin Ebru , Liljeqvist Jan-Åke , Brune Mats , Foà Robin , Aurelius Johan , Martner Anna , Hellstrand Kristoffer , Thorén Fredrik B.
Published: April 2023

Supplementary figures and table
Supplementary Table S1 from Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability
Authors: Moynihan Kelly D. , Holden Rebecca L. , Mehta Naveen K. , Wang Chensu , Karver Mark R. , Dinter Jens , Liang Simon , Abraham Wuhbet , Melo Mariane B. , Zhang Angela Q. , Li Na , Gall Sylvie Le , Pentelute Bradley L. , Irvine Darrell J.
Published: April 2023

Supplementary Table S1
Figure S5 from A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Authors: Chan Wing Keung , Kang Siwen , Youssef Youssef , Glankler Erin N. , Barrett Emma R. , Carter Alex M. , Ahmed Elshafa H. , Prasad Aman , Chen Luxi , Zhang Jianying , Benson Don M. , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

Soluble CS1 proteins and NKG2D-Fc did not affect the anti-CS1-NKG2D biAb-induced cytotoxicity of PBMCs against MM.1S
Supplementary Figure S3 from Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability
Authors: Moynihan Kelly D. , Holden Rebecca L. , Mehta Naveen K. , Wang Chensu , Karver Mark R. , Dinter Jens , Liang Simon , Abraham Wuhbet , Melo Mariane B. , Zhang Angela Q. , Li Na , Gall Sylvie Le , Pentelute Bradley L. , Irvine Darrell J.
Published: April 2023

Supplementary Figure S3
Supplementary Figure 1 from Combining DNA Vaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4+ and CD8+ T-cell Responses
Authors: Mei Yu , Zhao Lixiang , Liu Yonghao , Gong Huanle , Song Yuan , Lei Lei , Zhu Ying , Jin Ziqi , Ma Shoubao , Hu Bo , Sun Qing , Liu Haiyan
Published: April 2023

Representative flow cytometry plots for intracellular staining of TNF-alpha, IFN-gamma and IL-2 by gating on CD4+ or CD8+ T cells from splenocytes stimulated with B16-F10 lysates on day 14 in subcutaneous melanoma model.
Supplemental Figure 2 from PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF
Authors: Goyal Girija , Wong Karrie , Nirschl Christopher J. , Souders Nicholas , Neuberg Donna , Anandasabapathy Niroshana , Dranoff Glenn
Published: April 2023

S2. Impact of PPAR-γ deletion on the expression of the PPAR-γ-associated KEGG module and the profile of tumor-infiltrating leukocytes.
Supplementary Data Legends from Antagonism of IAPs Enhances CAR T-cell Efficacy
Authors: Michie Jessica , Beavis Paul A. , Freeman Andrew J. , Vervoort Stephin J. , Ramsbottom Kelly M. , Narasimhan Vignesh , Lelliott Emily J. , Lalaoui Najoua , Ramsay Robert G. , Johnstone Ricky W. , Silke John , Darcy Phillip K. , Voskoboinik Ilia , Kearney Conor J. , Oliaro Jane
Published: April 2023

Supplementary data legends
Figure S5 from Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer
Authors: Pfannenstiel Lukas W. , Diaz-Montero C. Marcela , Tian Ye F. , Scharpf Joseph , Ko Jennifer S. , Gastman Brian R.
Published: April 2023

Supplementary Figure 5. Pan T cells were isolated from human patient PBMC or mouse splenocytes using negative magnetic bead selection. Cells were then stained for CD3 CD8 PD-1 and Tim-3 and analyzed by FACS. Dot plots on the left are gated on CD3+ CD8+ cells. Bar graph on the left is representative of five patients or mice.